Research Background

This clinical trial aims to develop an immuno‑positron emission tomography (immunoPET) approach using the cell‑surface antigen Trop2. Trop2 is overexpressed in a variety of solid tumors, making it an attractive diagnostic target. Conventional PET imaging relies on metabolic activity, whereas immunoPET couples antibodies with radioactive isotopes to enhance tumor specificity. Consequently, it is expected to aid early cancer detection and precise staging.

Clinical Design

The study is conducted as a combined Phase 2/3 trial and is currently enrolling. Initiated on 23 December 2024, the trial is sponsored by RenJi Hospital and includes multiple solid tumors (bladder, prostate, lung, etc.). The primary endpoints are the diagnostic performance and safety of the immunoPET imaging, with comparative imaging characteristics evaluated across tumor types. Enrolled participants are adult patients requiring diagnostic work‑up for the respective cancers.

Differentiators and Expected Benefits

ImmunoPET offers higher tumor specificity than conventional PET, reducing false‑positive findings. By conjugating a Trop2‑targeted antibody with a radioactive isotope, even microscopic metastatic lesions may become visible. This capability can substantially improve pre‑operative lesion assessment and treatment‑response monitoring. Moreover, applicability across multiple tumor types positions the technology as a potential universal diagnostic platform.

Market and Impact

The diagnostic imaging market is valued at several billions of dollars annually, and immunoPET technology holds significant growth potential. A successful Trop2‑based imaging agent could be deployed on existing PET scanners, lowering market entry barriers. Success would expand precision‑medicine pipelines linked to oncology therapeutics, enhancing the investment appeal of bio‑imaging companies.